Patent · US Active

Compositions and methods for inhibiting expression of the HAMP gene

US8791250B2 · kind B2 · utility

4Cited by

4References

20Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Tomoko Nakayama · Cambridge, US
Anke Geick · Bayreuth, DE
Pamela Tan · Kulmbach, DE
Herbert Y. Lin · Watertown, US

Key dates

Filing date	May 23, 2013
Grant date	Jul 29, 2014
Priority date	—
Expiry date	May 23, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/11
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.